Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q8WTS1

UPID:
ABHD5_HUMAN

ALTERNATIVE NAMES:
Abhydrolase domain-containing protein 5; Lipid droplet-binding protein CGI-58

ALTERNATIVE UPACC:
Q8WTS1; B2R9K0; Q9Y369

BACKGROUND:
The protein 1-acylglycerol-3-phosphate O-acyltransferase ABHD5, with aliases such as Abhydrolase domain-containing protein 5 and Lipid droplet-binding protein CGI-58, is crucial in lipid metabolism. It acts as a coenzyme A-dependent lysophosphatidic acid acyltransferase, playing a key role in phosphatidic acid production, triacylglycerol storage regulation, keratinocyte differentiation, and lipid droplet fusion.

THERAPEUTIC SIGNIFICANCE:
Mutations in ABHD5 are responsible for Chanarin-Dorfman syndrome, indicating its critical role in lipid metabolism and suggesting its potential as a target for therapeutic intervention. Exploring ABHD5's functions could open doors to novel therapeutic strategies for lipid metabolism disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.